(News Bulletin 247) – AlphaValue renewed its buy recommendation on Sanofi on Wednesday, with a target price of 132 euros corresponding to an upside potential of 38%.
At a time when other securities in the sector such as Novo Nordisk or Eli Lilly are focusing the attention of investors, the research office believes that it is also time to look into the French pharmaceutical giant, of which it praises the ‘silent performances ‘.
Over the past five years, Sanofi has seen its profitability as its stock market valuation progress at a steady pace, despite the difficulties the laboratory has had to face, he points out.
Regarding its prospects, not only does its star drug Dupixent still show significant growth potential, but the group also has promising projects in other areas, notes AlphaValue.
With a current PER of 15x compared to a historical average of 20x over the period 2013-2022, the stock is now showing a discounted valuation which makes the research firm say that the stock represents an attractive investment opportunity.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
